Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT-02287 in early Parkinson's disease
NCT07280299Phase 2Not yet recruiting
- Sponsor
- Gain Therapeutics
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of rexaceract in Parkinson's disease (PD), sponsored by Gain Therapeutics. Planned start May 2026; status: not yet recruiting.
02
Drugs
rexaceract
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07280299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280299.